Celecoxib and Etoricoxib are two selective COX-2 inhibitors approved for complex diseases and disorders such as rheumatoid arthritis, neurodegenerative diseases and cardiovascular disorders (22). This evidence concerns the gene PTGS2 and rheumatoid arthritis.